Strontium ranelate, used for the treatment of osteoporosis in post-menopausal women and adult men at high risk of bone fracture, will be discontinued worldwide in August 2017. Practices need to urgently identify patients on this therapy and review treatment.
A new pathway has been endorsed by Barts Health NHS Trust Rheumatology Service for the management of the Strontium discontinuation. The pathway guides the process for GPs to determine continued need for treatment, and alternative options to be considered if needed.
Referral forms are included in the pathway which can found in the download section.